![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KCNQ5 |
Gene summary for KCNQ5 |
![]() |
Gene information | Species | Human | Gene symbol | KCNQ5 | Gene ID | 56479 |
Gene name | potassium voltage-gated channel subfamily Q member 5 | |
Gene Alias | Kv7.5 | |
Cytomap | 6q13 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9NR82 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56479 | KCNQ5 | RNA-P17T-P17T-2 | Human | Lung | IAC | 6.80e-05 | 7.24e-01 | 0.3371 |
56479 | KCNQ5 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.13e-06 | 8.53e-01 | 0.343 |
56479 | KCNQ5 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 6.57e-01 | 0.3385 |
56479 | KCNQ5 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.77e-07 | 7.44e-01 | 0.3329 |
56479 | KCNQ5 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.03e-03 | 3.90e-01 | 0.1829 |
56479 | KCNQ5 | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.31e-02 | 3.39e-01 | 0.1835 |
56479 | KCNQ5 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.14e-03 | 3.59e-01 | 0.1859 |
56479 | KCNQ5 | 047563_1562-all-cells | Human | Prostate | BPH | 2.54e-16 | 5.95e-01 | 0.0791 |
56479 | KCNQ5 | 048752_1579-all-cells | Human | Prostate | BPH | 6.95e-66 | 1.19e+00 | 0.1008 |
56479 | KCNQ5 | 052095_1628-all-cells | Human | Prostate | BPH | 7.88e-50 | 1.03e+00 | 0.1032 |
56479 | KCNQ5 | 052097_1595-all-cells | Human | Prostate | BPH | 7.16e-52 | 1.17e+00 | 0.0972 |
56479 | KCNQ5 | 052099_1652-all-cells | Human | Prostate | BPH | 1.58e-52 | 1.15e+00 | 0.1038 |
56479 | KCNQ5 | Dong_P5 | Human | Prostate | Tumor | 3.48e-16 | 1.48e-01 | 0.053 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCNQ5 | SNV | Missense_Mutation | rs140171454 | c.1975N>A | p.Ala659Thr | p.A659T | Q9NR82 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
KCNQ5 | SNV | Missense_Mutation | c.1563N>C | p.Glu521Asp | p.E521D | Q9NR82 | protein_coding | tolerated(0.62) | benign(0.02) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
KCNQ5 | SNV | Missense_Mutation | c.1737N>T | p.Met579Ile | p.M579I | Q9NR82 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
KCNQ5 | SNV | Missense_Mutation | c.451G>A | p.Glu151Lys | p.E151K | Q9NR82 | protein_coding | deleterious(0.01) | benign(0.129) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
KCNQ5 | SNV | Missense_Mutation | rs750945357 | c.2039T>C | p.Val680Ala | p.V680A | Q9NR82 | protein_coding | tolerated(0.47) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KCNQ5 | SNV | Missense_Mutation | novel | c.2163C>A | p.Phe721Leu | p.F721L | Q9NR82 | protein_coding | tolerated(0.64) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KCNQ5 | SNV | Missense_Mutation | c.2531N>G | p.Asp844Gly | p.D844G | Q9NR82 | protein_coding | tolerated_low_confidence(0.57) | benign(0.217) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
KCNQ5 | SNV | Missense_Mutation | c.634G>A | p.Ala212Thr | p.A212T | Q9NR82 | protein_coding | deleterious(0.04) | probably_damaging(0.981) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
KCNQ5 | SNV | Missense_Mutation | c.886N>C | p.Ser296Pro | p.S296P | Q9NR82 | protein_coding | tolerated(0.2) | benign(0.112) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
KCNQ5 | SNV | Missense_Mutation | c.2005N>A | p.Glu669Lys | p.E669K | Q9NR82 | protein_coding | deleterious(0) | possibly_damaging(0.459) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | irinotecan | IRINOTECAN | 25127363 | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | activator | CHEMBL266510 | FLINDOKALNER | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | activator | 135650748 | ||
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL41355 | EZOGABINE | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | activator | 135650001 | FLINDOKALNER | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135651249 | ||
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL284348 | DALFAMPRIDINE | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL2107762 | NERISPIRDINE | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200728 | GUANIDINE HYDROCHLORIDE | |
56479 | KCNQ5 | ION CHANNEL, DRUGGABLE GENOME | inhibitor | 135650523 | LINOPIRDINE |
Page: 1 2 |